A holistic review of colon cancer causes diagnosis and current therapies| International Journal of Innovative Science and Research Technology

A Holistic Review of Colon Cancer: Causes, Diagnosis, and Current Therapies

Authors : Syeda Bushra Hashim

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/3kcdkw7y

Scribd : https://tinyurl.com/3xftrawz

DOI : https://doi.org/10.38124/ijisrt/25jul852

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Both men and women can develop colorectal cancer, which is the third most common and deadliest disease in the UK. Compared to colon cancer, the third most common cancer worldwide, lung cancer has a higher mortality rate. Based on incidence rates, colorectal cancer ranks as the third most common cancer in men and the second in women. Individuals with a family history of colorectal cancer are significantly more likely to develop the disease. As the colonic epithelium progresses from normal to dysplasia and eventually to cancer, genetic changes occur. Possible signs of colon cancer include rectal haemorrhage, an abdominal mass, abdominal pain, changes in bowel habits, unexplained weight loss, and iron- deficiency anaemia. For stage 0 cancer, a procedure called a colonoscopy is used to remove cancerous cells. Localised therapy is the primary treatment option if the cancer is small, early-stage, and has not spread to other organs. To fully remove the affected area, a surgical operation such as hemicolectomy, partial colectomy, or segmental resection may be performed, which can involve a colonoscopy or excising the section of colon containing the cancer.

Keywords : Vascular Endothelial Growth Factor, Colorectal Cancer, Inflammatory Bowel Disease, Colonoscopy, and Bevacizumab.

References :

Murphy N, Moreno V, Hughes DJ, Vodicka L, Vodicka P, Aglago EK, et al. Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med [Internet]. 2019;69:2–9.
Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers (Basel) [Internet]. 2021;13(9):2025.
East JE, Vieth M, Rex DK. Serrated lesions in colorectal cancer screening: detection, resection, pathology and surveillance. Gut [Internet]. 2015;64(6):991–1000.
Meester RGS, Doubeni CA, Zauber AG, Goede SL, Levin TR, Corley DA, et al. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018: Benefits of 80% CRC Screening by 2018. Cancer [Internet]. 2015;121(13):2281–5.
Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med [Internet]. 2014;370(14):1298–306.
Cruz A, Carvalho CM, Cunha A, Crespo A, Iglesias Á, García-Nimo L, et al. Faecal diagnostic biomarkers for colorectal cancer. Cancers (Basel) [Internet]. 2021;13(21):5568.
Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel) [Internet]. 2020;9(3):34.
Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell [Internet]. 2015;161(2):205–14.
Hazama S, Nakamura Y, Tanaka H, Hirakawa K, Tahara K, Shimizu R, et al. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med [Internet]. 2014;12(1):108.
Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa A-E. Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements. Int J Mol Sci [Internet]. 2020;22(1):130.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018;68(6):394–424.
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature [Internet]. 2012;487(7407):330–7.
Leslie A, Carey FA, Pratt NR, Steele RJC. The colorectal adenoma–carcinoma sequence. Br J Surg [Internet]. 2002;89(7):845–60.
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: A review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel) [Internet]. 2022;14(7):1732.Navarro M., Nicolas A., Ferrandez A., Lanas A. Colorectal cancer population screening programs worldwide in 2016: An update. World J. Gastroenterol. 2017;23:3632–3642. doi: 10.3748/wjg.v23.i20.3632.
Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology [Internet]. 1997;112(2):594–642
Barnell GM, Ajayi O, Tolan-Riley A, Dixon MR. A team-based approach to anal cancer screening and prevention. Dis Colon Rectum [Internet]. 2019;62(3):e13.
Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging: The Eighth Edition AJCC Cancer Staging Manual. CA Cancer J Clin [Internet]. 2017;67(2):93–9.
Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, et al. Colorectal cancer: A review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel) [Internet]. 2022;14(7):1732.
Fabregas JC, Ramnaraign B, George TJ. Clinical updates for colon cancer care in 2022. Clin Colorectal Cancer [Internet]. 2022;21(3):198–203.
Fong V, Chang Z, Lillemoe DC, Nipp KD, Tanabe RD, Qadan KK. Contemporary Opportunity for Prehabilitation as Part of an Enhanced Recovery after Surgery Pathway in Colorectal Surgery. Clin Colon Rectal Surg. 2019;32(2):95–101.
Birch RJ, Burr N, Subramanian V, Tiernan JP, Hull MA, Finan P, et al. Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: An English population-based study. Am J Gastroenterol [Internet]. 2022;117(11):1858–70.
Stoffel EM, Murphy CC. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroenterology [Internet]. 2020;158(2):341–53

Both men and women can develop colorectal cancer, which is the third most common and deadliest disease in the UK. Compared to colon cancer, the third most common cancer worldwide, lung cancer has a higher mortality rate. Based on incidence rates, colorectal cancer ranks as the third most common cancer in men and the second in women. Individuals with a family history of colorectal cancer are significantly more likely to develop the disease. As the colonic epithelium progresses from normal to dysplasia and eventually to cancer, genetic changes occur. Possible signs of colon cancer include rectal haemorrhage, an abdominal mass, abdominal pain, changes in bowel habits, unexplained weight loss, and iron- deficiency anaemia. For stage 0 cancer, a procedure called a colonoscopy is used to remove cancerous cells. Localised therapy is the primary treatment option if the cancer is small, early-stage, and has not spread to other organs. To fully remove the affected area, a surgical operation such as hemicolectomy, partial colectomy, or segmental resection may be performed, which can involve a colonoscopy or excising the section of colon containing the cancer.

Keywords : Vascular Endothelial Growth Factor, Colorectal Cancer, Inflammatory Bowel Disease, Colonoscopy, and Bevacizumab.